Hyperthermia stimulates HIV-1 replication

PLoS Pathogens

Volumn 8, Issue 7, 2012, Pages 35-

  Roesch, Ferdinand ^a,b,c   Meziane, Oussama ^b,d   Kula, Anna ^e   Nisole, Sébastien ^a   Porrot, Françoise ^a,b   Anderson, Ian ^f   Mammano, Fabrizio ^g,h   Fassati, Ariberto ^f   Marcello, Alessandro ^e   Benkirane, Monsef ^b,d   Schwartz, Olivier ^a,b  

^a INSTITUT PASTEUR   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d INSTITUTE OF HUMAN GENETICS   (France)

^e INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g SAINT LOUIS HOSPITAL   (France)

^h UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 90; NEVIRAPINE; TANESPIMYCIN; TRANSACTIVATOR PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; BODY TEMPERATURE; CD4+ T LYMPHOCYTE; CELL CULTURE; CONTROLLED STUDY; FEMALE; HEAT SHOCK; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPERTHERMIA; LATENT VIRUS INFECTION; LONG TERMINAL REPEAT; MEDIATOR; PROMOTER REGION; PROTEIN LOCALIZATION; PROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS ENTRY; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS STRAIN;

BENZOQUINONES; CD4-POSITIVE T-LYMPHOCYTES; FEVER; GENE EXPRESSION REGULATION, VIRAL; HELA CELLS; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HOT TEMPERATURE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; JURKAT CELLS; LACTAMS, MACROCYCLIC; PROMOTER REGIONS, GENETIC; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTIONAL ACTIVATION; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84864628996     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002792     Document Type: Article

References (88)

1. Ostberg JR, Repasky EA, (2006) Emerging evidence indicates that physiologically relevant thermal stress regulates dendritic cell function. Cancer Immunol Immunother 55: 292-298.
2. Hasday JD, Fairchild KD, Shanholtz C, (2000) The role of fever in the infected host. Microbes Infect 2: 1891-1904.
3. Evans SS, Wang WC, Bain MD, Burd R, Ostberg JR, et al. (2001) Fever-range hyperthermia dynamically regulates lymphocyte delivery to high endothelial venules. Blood 97: 2727-2733.
4. Ostberg JR, Dayanc BE, Yuan M, Oflazoglu E, Repasky EA, (2007) Enhancement of natural killer (NK) cell cytotoxicity by fever-range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells. J Leukoc Biol 82: 1322-1331.
5. van Bruggen I, Robertson TA, Papadimitriou JM, (1991) The effect of mild hyperthermia on the morphology and function of murine resident peritoneal macrophages. Exp Mol Pathol 55: 119-134.
6. Ishida Y, Hiraki A, Hirayama E, Koga Y, Kim J, (2002) Temperature-sensitive viral infection: inhibition of hemagglutinating virus of Japan (Sendai virus) infection at 41 degrees. Intervirology 45: 125-135.
7. De Marco A, Santoro MG, (1993) Antiviral effect of short hyperthermic treatment at specific stages of vesicular stomatitis virus replication cycle. J Gen Virol 74 (Pt 8): 1685-1690.
8. Virgilio PL, Godinho-Netto MC, Carvalho M.G, (1997) Previous heat shock treatment inhibits Mayaro virus replication in human lung adenocarcinoma (A549) cells. Res Virol 148: 333-342.
9. Chavez-Salinas S, Ceballos-Olvera I, Reyes-Del Valle J, Medina F, Del Angel RM, (2008) Heat shock effect upon dengue virus replication into U937 cells. Virus Res 138: 111-118.
10. Lopez C, Fitzgerald PA, Siegal FP, (1983) Severe acquired immune deficiency syndrome in male homosexuals: diminished capacity to make interferon-alpha in vitro associated with severe opportunistic infections. J Infect Dis 148: 962-966.
11. Zerbini M, Musiani M, La Placa M, (1985) Effect of heat shock on Epstein-Barr virus and cytomegalovirus expression. J Gen Virol 66 (Pt 3): 633-636.
12. Kaper JM, Geletka LM, Wu GS, Tousignant ME, (1995) Effect of temperature on cucumber mosaic virus satellite-induced lethal tomato necrosis is helper virus strain dependent. Arch Virol 140: 65-74.
13. Kido K, Tanaka C, Mochizuki T, Kubota K, Ohki T, et al. (2008) High temperatures activate local viral multiplication and cell-to-cell movement of Melon necrotic spot virus but restrict expression of systemic symptoms. Phytopathology 98: 181-186.
14. Modjarrad K, Vermund SH, (2010) Effect of treating co-infections on HIV-1 viral load: a systematic review. Lancet Infect Dis 10: 455-463.
15. McShane H, (2005) Co-infection with HIV and TB: double trouble. Int J STD AIDS 16: 95-100 quiz 101.
16. Idemyor V, (2007) Human immunodeficiency virus (HIV) and malaria interaction in sub-Saharan Africa: the collision of two Titans. HIV Clin Trials 8: 246-253.
17. Barnabas RV, Webb EL, Weiss HA, Wasserheit JN, (2011) The role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis. AIDS 25: 1559-1573.
18. Kiyingi HS, Egwang TG, Nannyonga M, (2010) Prolonged elevation of viral loads in HIV-1-infected children in a region of intense malaria transmission in Northern Uganda: a prospective cohort study. Pan Afr Med J 7: 11.
19. Bentwich Z, (2003) Concurrent infections that rise the HIV viral load. J HIV Ther 8: 72-75.
20. Collins KR, Quinones-Mateu ME, Toossi Z, Arts EJ, (2002) Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. AIDS Rev 4: 165-176.
21. Toossi Z, (2003) Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis 188: 1146-1155.
22. Decrion AZ, Dichamp I, Varin A, Herbein G, (2005) HIV and inflammation. Curr HIV Res 3: 243-259.
23. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF, (2010) The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 10: 11-23.
24. Haase AT, (2010) Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464: 217-223.
25. Brenchley JM, Silvestri G, Douek DC, (2010) Nonprogressive and progressive primate immunodeficiency lentivirus infections. Immunity 32: 737-742.
26. Cameron PU, Saleh S, Sallmann G, Solomon A, Wightman F, et al. (2010) Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci U S A 107: 16934-16939.
27. Poli G, Bressler P, Kinter A, Duh E, Timmer WC, et al. (1990) Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms. J Exp Med 172: 151-158.
28. Poli G, Kinter AL, Fauci AS, (1994) Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist. Proc Natl Acad Sci USA 91: 108-112.
29. Fauci AS, (1996) Host factors and the pathogenesis of HIV-induced disease. Nature 384: 529-534.
30. Kedzierska K, Crowe SM, (2001) Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother 12: 133-150.
31. Stanley SK, Bressler PB, Poli G, Fauci AS, (1990) Heat shock induction of HIV production from chronically infected promonocytic and T cell lines. J Immunol 145: 1120-1126.
32. Hashimoto K, Baba M, Gohnai K, Sato M, Shigeta S, (1996) Heat shock induces HIV-1 replication in chronically infected promyelocyte cell line OM10.1. Arch Virol 141: 439-447.
33. Furlini G, Re MC, Musiani M, Zerbini ML, La Placa M, (1990) Enhancement of HIV-1 marker detection in cell cultures treated with mild heat-shock. Microbiologica 13: 21-26.
34. Harada S, Yusa K, Monde K, Akaike T, Maeda Y, (2005) Influence of membrane fluidity on human immunodeficiency virus type 1 entry. Biochem Biophys Res Commun 329: 480-486.
35. Wiskerchen M, Muesing MA, (1995) Identification and characterization of a temperature-sensitive mutant of human immunodeficiency virus type 1 by alanine scanning mutagenesis of the integrase gene. J Virol 69: 597-601.
36. Calderwood SK, (2010) Heat shock proteins in breast cancer progression-a suitable case for treatment? Int J Hyperthermia 26: 681-685.
37. Allegra A, Sant'antonio E, Penna G, Alonci A, D'Angelo A, et al. (2011) Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors. Eur J Haematol 86: 93-110.
38. Ciocca DR, Fanelli MA, Cuello-Carrion FD, Castro GN, (2010) Heat shock proteins in prostate cancer: from tumorigenesis to the clinic. Int J Hyperthermia 26: 737-747.
39. Torigoe T, Tamura Y, Sato N, (2009) Heat shock proteins and immunity: application of hyperthermia for immunomodulation. Int J Hyperthermia 25: 610-616.
40. Bolhassani A, Rafati S, (2008) Heat-shock proteins as powerful weapons in vaccine development. Expert Rev Vaccines 7: 1185-1199.
41. Brenner BG, Wainberg MA, (1999) Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection. Infect Dis Obstet Gynecol 7: 80-90.
42. Gurer C, Cimarelli A, Luban J, (2002) Specific incorporation of heat shock protein 70 family members into primate lentiviral virions. J Virol 76: 4666-4670.
43. Agostini I, Popov S, Li J, Dubrovsky L, Hao T, et al. (2000) Heat-shock protein 70 can replace viral protein R of HIV-1 during nuclear import of the viral preintegration complex. Exp Cell Res 259: 398-403.
44. Bukrinsky M, Zhao Y, (2004) Heat-shock proteins reverse the G2 arrest caused by HIV-1 viral protein R. DNA Cell Biol 23: 223-225.
45. Iordanskiy S, Zhao Y, DiMarzio P, Agostini I, Dubrovsky L, et al. (2004) Heat-shock protein 70 exerts opposing effects on Vpr-dependent and Vpr-independent HIV-1 replication in macrophages. Blood 104: 1867-1872.
46. Iordanskiy S, Zhao Y, Dubrovsky L, Iordanskaya T, Chen M, et al. (2004) Heat shock protein 70 protects cells from cell cycle arrest and apoptosis induced by human immunodeficiency virus type 1 viral protein R. J Virol 78: 9697-9704.
47. Kumar M, Rawat P, Khan SZ, Dhamija N, Chaudhary P, et al. (2011) Reciprocal regulation of human immunodeficiency virus-1 gene expression and replication by heat shock proteins 40 and 70. J Mol Biol 410: 944-958.
48. Vozzolo L, Loh B, Gane PJ, Tribak M, Zhou L, et al. (2010) Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein. J Biol Chem 285: 39314-39328.
49. Rawat P, Mitra D, (2011) Cellular heat shock factor 1 positively regulates human immunodeficiency virus-1 gene expression and replication by two distinct pathways. Nucleic Acids Res 39: 5879-5892.
50. Joshi P, Stoddart CA, (2011) Impaired infectivity of ritonavir-resistant HIV is rescued by heat shock protein 90AB1. J Biol Chem 286: 24581-24592.
51. Cavrois M, De Noronha C, Greene WC, (2002) A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol 20: 1151-1154.
52. Cavrois M, Neidleman J, Bigos M, Greene WC, (2004) Fluorescence resonance energy transfer-based HIV-1 virion fusion assay. Methods Mol Biol 263: 333-344.
53. Casartelli N, Sourisseau M, Feldmann J, Guivel-Benhassine F, Mallet A, et al. (2010) Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog 6: e1000955.
54. Piskareva O, Denmukhametova S, Schmatchenko V, (2003) Functional reverse transcriptase encoded by the human LINE-1 from baculovirus-infected insect cells. Protein Expr Purif 28: 125-130.
55. Huber HE, McCoy JM, Seehra JS, Richardson CC, (1989) Human immunodeficiency virus 1 reverse transcriptase. Template binding, processivity, strand displacement synthesis, and template switching. J Biol Chem 264: 4669-4678.
56. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, et al. (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 94: 13193-13197.
57. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
58. Lafeuillade A, Stevenson M, (2011) The search for a cure for persistent HIV reservoirs. AIDS Rev 13: 63-66.
59. Marcello A, (2006) Latency: the hidden HIV-1 challenge. Retrovirology 3: 7.
60. Chun TW, Davey RT Jr, Engel D, Lane HC, Fauci AS, (1999) Re-emergence of HIV after stopping therapy. Nature 401: 874-875.
61. Moriuchi H, Moriuchi M, Mizell SB, Ehler LA, Fauci AS, (2000) In vitro reactivation of human immunodeficiency virus 1 from latently infected, resting CD4+ T cells after bacterial stimulation. J Infect Dis 181: 2041-2044.
62. Williams SA, Chen LF, Kwon H, Fenard D, Bisgrove D, et al. (2004) Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 279: 42008-42017.
63. Dieudonne M, Maiuri P, Biancotto C, Knezevich A, Kula A, et al. (2009) Transcriptional competence of the integrated HIV-1 provirus at the nuclear periphery. EMBO J 28: 2231-2243.
64. Gallastegui E, Millan-Zambrano G, Terme JM, Chavez S, Jordan A, (2011) Chromatin reassembly factors are involved in transcriptional interference promoting HIV latency. J Virol 85: 3187-3202.
65. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E, (2009) Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 5: e1000495.
66. Jordan A, Bisgrove D, Verdin E, (2003) HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 22: 1868-1877.
67. O'Keeffe B, Fong Y, Chen D, Zhou S, Zhou Q, (2000) Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription. J Biol Chem 275: 279-287.
68. Boireau S, Maiuri P, Basyuk E, de la Mata M, Knezevich A, et al. (2007) The transcriptional cycle of HIV-1 in real-time and live cells. J Cell Biol 179: 291-304.
69. Maiuri P, Knezevich A, Bertrand E, Marcello A, (2011) Real-time imaging of the HIV-1 transcription cycle in single living cells. Methods 53: 62-67.
70. Kula A, Guerra J, Knezevich A, Kleva D, Myers MP, et al. (2011) Characterization of the HIV-1 RNA associated proteome identifies Matrin 3 as a nuclear cofactor of Rev function. Retrovirology 8: 60.
71. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, et al. (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42: 260-266.
72. Obermann WM, Sondermann H, Russo AA, Pavletich NP, Hartl FU, (1998) In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol 143: 901-910.
73. Panaretou B, Prodromou C, Roe SM, O'Brien R, Ladbury JE, et al. (1998) ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J 17: 4829-4836.
74. Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, et al. (2011) Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol 152: 367-379.
75. Yamaki H, Nakajima M, Shimotohno KW, Tanaka N, (2011) Molecular basis for the actions of Hsp90 inhibitors and cancer therapy. J Antibiot (Tokyo) 64: 635-644.
76. Basha W, Kitagawa R, Uhara M, Imazu H, Uechi K, et al. (2005) Geldanamycin, a potent and specific inhibitor of Hsp90, inhibits gene expression and replication of human cytomegalovirus. Antivir Chem Chemother 16: 135-146.
77. Nakagawa S, Umehara T, Matsuda C, Kuge S, Sudoh M, et al. (2007) Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem Biophys Res Commun 353: 882-888.
78. Chase G, Deng T, Fodor E, Leung BW, Mayer D, et al. (2008) Hsp90 inhibitors reduce influenza virus replication in cell culture. Virology 377: 431-439.
79. Castorena KM, Weeks SA, Stapleford KA, Cadwallader AM, Miller DJ, (2007) A functional heat shock protein 90 chaperone is essential for efficient flock house virus RNA polymerase synthesis in Drosophila cells. J Virol 81: 8412-8420.
80. Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, et al. (2010) HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 329: 174-180.
81. Yang HC, (2011) Primary cell models of HIV latency. Curr Opin HIV AIDS 6: 62-67.
82. Rong L, Perelson AS, (2009) Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol 260: 308-331.
83. Sulkowski MS, Chaisson RE, Karp CL, Moore RD, Margolick JB, et al. (1998) The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults. J Infect Dis 178: 1642-1648.
84. Kublin JG, Patnaik P, Jere CS, Miller WC, Hoffman IF, et al. (2005) Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 365: 233-240.
85. Vendrame D, Sourisseau M, Perrin V, Schwartz O, Mammano F, (2009) Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer. J Virol 83: 10527-10537.
86. Nobile C, Moris A, Porrot F, Sol-Foulon N, Schwartz O, (2003) Inhibition of human immunodeficiency virus type 1 Env-mediated fusion by DC-SIGN. J Virol 77: 5313-5323.
87. Treand C, du Chene I, Bres V, Kiernan R, Benarous R, et al. (2006) Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter. EMBO J 25: 1690-1699.
88. Marcello A, Ferrari A, Pellegrini V, Pegoraro G, Lusic M, et al. (2003) Recruitment of human cyclin T1 to nuclear bodies through direct interaction with the PML protein. EMBO J 22: 2156-2166.